IP Library › Granted Patent US 7,470,431
Granted Patent B2
US 7,470,431 · App. 10/655,889 · Granted Dec 30, 2008

Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,470,431
App. No.
10/655,889
Granted
Dec 30, 2008
Kind
B2
Abstract

The present invention related to methods for treating neurological-urological conditions associated with prostate cancer or methods of treatment of prostate cancer, which is accomplished by administration of botulinum toxin to the patient.

Claims (7)

1. A method for alleviating a condition associated with prostate cancer selected from the group consisting of prostatic enlargement, urinary incontinence, urinary retention, and urge-type dysfunction, the method comprising the step of injecting a therapeutically effective amount of botulinum toxin type A into the prostate gland of a patient with prostate cancer, thereby alleviating said condition associated with prostate cancer.

2. The method of claim 1 , wherein the condition associated with prostate cancer is urinary incontinence.

3. The method according to claim 1 , where the patient is a human.

4. The method of claim 1 , wherein the condition is prostatic enlargement.

5. The method of claim 1 , wherein the therapeutically effective amount of botulinum toxin type A is up to 2500 units.

6. The method of claim 1 , wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A.

7. The method of claim 1 , wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: THE REGENTS OF THE UNIVERSITY OF COLORADO
To: ALLERGAN, INC.
Reel/Frame 036260/0570 →